OneSource Specialty Pharma Ltd. Approves Q3 and Q4 2025 Financial Results

OneSource Specialty Pharma Ltd., formerly Stelis Biopharma Limited, has approved the unaudited financial results for the quarter and nine months ended December 31, 2025. The company's revenue from operations stands at 2,902.20 million for Q4 and 9,864.19 million for the nine months ended period. The total income for Q4 is 2,948.44 million and 13,172.71 million for the nine months ended period. The company's profit before tax for Q4 is 68.21 million and loss before tax for the nine months ended period is 2.69 million. The profit after tax for Q4 is 200.00 million and loss after tax for the nine months ended period is 1,548.77 million. The total comprehensive income for the period is 193.10 million.